FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591477775> ?p ?o ?g. }

• W2591477775 endingPage "21166" @default.
• W2591477775 startingPage "21153" @default.
• W2591477775 abstract "// Dominik Schnerch 1 , Julia Schüler 2 , Marie Follo 1 , Julia Felthaus 1 , Dagmar Wider 1 , Kathrin Klingner 2 , Christine Greil 1 , Justus Duyster 1 , Monika Engelhardt 1 , Ralph Wäsch 1 1 Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany 2 Oncotest GmbH, Freiburg, Germany Correspondence to: Ralph Wäsch, email: ralph.waesch@uniklinik-freiburg.de Keywords: AML, antimitotic therapy, APC/C, mitotic slippage, proteasome inhibition Received: December 22, 2016      Accepted: February 07, 2017      Published: February 18, 2017 ABSTRACT Elderly and frail patients, diagnosed with acute myeloid leukemia (AML) and ineligible to undergo intensive treatment, have a dismal prognosis. The small molecule inhibitor volasertib induces a mitotic block via inhibition of polo-like kinase 1 and has shown remarkable anti-leukemic activity when combined with low-dose cytarabine. We have demonstrated that AML cells are highly vulnerable to cell death in mitosis yet manage to escape a mitotic block through mitotic slippage by sustained proteasome-dependent slow degradation of cyclin B. Therefore, we tested whether interfering with mitotic slippage through proteasome inhibition arrests and kills AML cells more efficiently during mitosis. We show that therapeutic doses of bortezomib block the slow degradation of cyclin B during a volasertib-induced mitotic arrest in AML cell lines and patient-derived primary AML cells. In a xenotransplant mouse model of human AML, mice receiving volasertib in combination with bortezomib showed superior disease control compared to mice receiving volasertib alone, highlighting the potential therapeutic impact of this drug combination." @default.
• W2591477775 created "2017-03-03" @default.
• W2591477775 creator A5002404403 @default.
• W2591477775 creator A5011908172 @default.
• W2591477775 creator A5034493142 @default.
• W2591477775 creator A5038973583 @default.
• W2591477775 creator A5045008064 @default.
• W2591477775 creator A5061176341 @default.
• W2591477775 creator A5063647828 @default.
• W2591477775 creator A5085654090 @default.
• W2591477775 creator A5088238455 @default.
• W2591477775 creator A5088789978 @default.
• W2591477775 date "2017-02-18" @default.
• W2591477775 modified "2023-09-23" @default.
• W2591477775 title "Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML <i>in vitro</i> and prolongs survival <i>in vivo</i>" @default.
• W2591477775 cites W1483395792 @default.
• W2591477775 cites W1679600454 @default.
• W2591477775 cites W169077027 @default.
• W2591477775 cites W1966967749 @default.
• W2591477775 cites W1967275407 @default.
• W2591477775 cites W1967508937 @default.
• W2591477775 cites W1970740484 @default.
• W2591477775 cites W1972163440 @default.
• W2591477775 cites W1988663387 @default.
• W2591477775 cites W2007314270 @default.
• W2591477775 cites W2009656063 @default.
• W2591477775 cites W2023678160 @default.
• W2591477775 cites W2028578770 @default.
• W2591477775 cites W2028984447 @default.
• W2591477775 cites W2034086671 @default.
• W2591477775 cites W2036012693 @default.
• W2591477775 cites W2040977036 @default.
• W2591477775 cites W2047185677 @default.
• W2591477775 cites W2048509801 @default.
• W2591477775 cites W2048938594 @default.
• W2591477775 cites W2053034826 @default.
• W2591477775 cites W2054439285 @default.
• W2591477775 cites W2060797544 @default.
• W2591477775 cites W2068556430 @default.
• W2591477775 cites W2077804275 @default.
• W2591477775 cites W2078651408 @default.
• W2591477775 cites W2087387230 @default.
• W2591477775 cites W2087488820 @default.
• W2591477775 cites W2101725260 @default.
• W2591477775 cites W2112998845 @default.
• W2591477775 cites W2118820477 @default.
• W2591477775 cites W2124110638 @default.
• W2591477775 cites W2124631783 @default.
• W2591477775 cites W2147124058 @default.
• W2591477775 cites W2149058047 @default.
• W2591477775 cites W2152007597 @default.
• W2591477775 cites W2154603906 @default.
• W2591477775 cites W2157287007 @default.
• W2591477775 cites W2169183166 @default.
• W2591477775 cites W2237124828 @default.
• W2591477775 doi "https://doi.org/10.18632/oncotarget.15503" @default.
• W2591477775 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5400573" @default.
• W2591477775 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28416751" @default.
• W2591477775 hasPublicationYear "2017" @default.
• W2591477775 type Work @default.
• W2591477775 sameAs 2591477775 @default.
• W2591477775 citedByCount "15" @default.
• W2591477775 countsByYear W25914777752017 @default.
• W2591477775 countsByYear W25914777752018 @default.
• W2591477775 countsByYear W25914777752019 @default.
• W2591477775 countsByYear W25914777752021 @default.
• W2591477775 countsByYear W25914777752022 @default.
• W2591477775 crossrefType "journal-article" @default.
• W2591477775 hasAuthorship W2591477775A5002404403 @default.
• W2591477775 hasAuthorship W2591477775A5011908172 @default.
• W2591477775 hasAuthorship W2591477775A5034493142 @default.
• W2591477775 hasAuthorship W2591477775A5038973583 @default.
• W2591477775 hasAuthorship W2591477775A5045008064 @default.
• W2591477775 hasAuthorship W2591477775A5061176341 @default.
• W2591477775 hasAuthorship W2591477775A5063647828 @default.
• W2591477775 hasAuthorship W2591477775A5085654090 @default.
• W2591477775 hasAuthorship W2591477775A5088238455 @default.
• W2591477775 hasAuthorship W2591477775A5088789978 @default.
• W2591477775 hasBestOaLocation W25914777751 @default.
• W2591477775 hasConcept C126322002 @default.
• W2591477775 hasConcept C143998085 @default.
• W2591477775 hasConcept C194409129 @default.
• W2591477775 hasConcept C2776364478 @default.
• W2591477775 hasConcept C2777478702 @default.
• W2591477775 hasConcept C2778367456 @default.
• W2591477775 hasConcept C2778729363 @default.
• W2591477775 hasConcept C502942594 @default.
• W2591477775 hasConcept C71924100 @default.
• W2591477775 hasConceptScore W2591477775C126322002 @default.
• W2591477775 hasConceptScore W2591477775C143998085 @default.
• W2591477775 hasConceptScore W2591477775C194409129 @default.
• W2591477775 hasConceptScore W2591477775C2776364478 @default.
• W2591477775 hasConceptScore W2591477775C2777478702 @default.
• W2591477775 hasConceptScore W2591477775C2778367456 @default.
• W2591477775 hasConceptScore W2591477775C2778729363 @default.
• W2591477775 hasConceptScore W2591477775C502942594 @default.
• W2591477775 hasConceptScore W2591477775C71924100 @default.
• W2591477775 hasIssue "13" @default.

• next